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However, we doubt that further studies will change
the current confusing situation. Is it sensible to increase
research efforts in this field any further just to exclude a
possible nil effect of NAC in RCIN? Given the amount
of data generated on this topic in recent years we believe
that it is unlikely that better protection against RCIN will
be achieved by additional trials as argued by Pannu et al
[4]. We therefore suggest that science should move on to
search for even better solutions.
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Reply from the Authors
We thank Drs. Koller and Rosenkranz for their inter-
est in our meta-analysis. They suggest that further study
of NAC for the prevention of contrast nephropathy may
be unjustified, given the negligible cost and side effect
profile of this agent. Further, they allude to the difficul-
ties faced by clinicians in deciding how best to prevent
contrast nephropathy in their patients. We struggled with
these issues during preparation of our manuscript, and
did not mean to imply that clinicians should not use NAC.
Rather, as we stated in our article, we believe that data
are insufficient to recommend that NAC become the stan-
dard of care for patients receiving radiocontrast.
This distinction is important because although the costs
associated with NAC administration may be negligible,
the potential consequences of recommending an ineffec-
tive therapy as the standard of care are not—from the
perspective of both clinicians and scientists.
For clinicians, NAC use may provide a false sense of
security—hydration may be ignored, other nephrotoxic
medications may not be discontinued as they should be, or
unnecessary contrast studies might be performed because
of the perception that NAC reduces the risk of contrast
nephropathy.
For scientists, such a recommendation may stifle fur-
ther research to find more effective prophylaxis. In addi-
tion, prematurely adopting NAC as the standard of care
would jeopardize the feasibility of placebo controlled tri-
als in the future.
We fully agree that clinicians should consider the use
of NAC (together with other interventions that reduce
the risk of contrast nephropathy) in patients who must
receive radiocontrast. However, like Drs. Koller and
Rosenkranz, we believe that further work is required to
define the optimal strategy for prevention of this serious
complication—with or without the use of NAC.
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